Jena Debasish, Sahoo Jagannatha, Barman Apurba, Dalai Anchal, Patel Suman
Department of Physical Medicine and Rehabilitation, AIIMS, Bhubaneswar, India.
Department of Anaesthesiology, SCB Medical College and Hospital, Cuttack, India.
Arch Rehabil Res Clin Transl. 2022 Jun;4(2):100188. doi: 10.1016/j.arrct.2022.100188. Epub 2022 Feb 27.
To report the demographic and clinical characteristics of 8 patients hospitalized with COVID-19 and presenting with neuropathic pain (NeuP).
A prospective case series with 1-month follow-up.
COVID-19-dedicated wards of a tertiary care center.
We included 8 consecutive cases of laboratory-confirmed cases of COVID-19 (by reverse transcription polymerase chain reaction) who presented with NeuP during the course of their acute hospitalization (N=8).
Not applicable.
A verbal rating scale was used to assess NeuP severity at presentation and at 1-month follow-up. The Douleur Neuropathique 4 questionnaire was used to diagnose NeuP at presentation.
Most patients were diagnosed as moderate to severe COVID-19 (6/8) and presented with mild to moderate NeuP (6/8). A substantial proportion of patients (4/8) displayed persistence of mild pain symptoms at 1-month follow-up. Furthermore, participants displayed a favorable response to gabapentinoids with or without antidepressants.
NeuP is a less commonly encountered symptom of COVID-19, but its early diagnosis and prompt management are of utmost importance. More studies including a larger cohort and longer follow-up are recommended for better understanding of COVID-19-associated NeuP.
报告8例因新型冠状病毒肺炎（COVID-19）住院且伴有神经性疼痛（NeuP）患者的人口统计学和临床特征。
一项随访1个月的前瞻性病例系列研究。
一家三级护理中心的COVID-19专用病房。
我们纳入了8例实验室确诊的COVID-19连续病例（通过逆转录聚合酶链反应确诊），这些患者在急性住院期间出现了NeuP（N = 8）。
不适用。
使用言语评定量表在就诊时和随访1个月时评估NeuP严重程度。使用神经病理性疼痛4问卷在就诊时诊断NeuP。
大多数患者被诊断为中度至重度COVID-19（6/8），并伴有轻度至中度NeuP（6/8）。相当一部分患者（4/8）在随访1个月时仍有轻度疼痛症状。此外，参与者对加巴喷丁类药物联合或不联合抗抑郁药反应良好。
NeuP是COVID-19较少见的症状，但其早期诊断和及时处理至关重要。建议开展更多研究，纳入更大队列并进行更长时间的随访，以更好地了解与COVID-19相关的NeuP。
